Price movement over the last 24 hours
Agilent Technologies Inc vs Global X Uranium ETF — how do they compare? Agilent Technologies Inc trades at $128.79 (market cap $37.04B), while Global X Uranium ETF trades at $41.22. The key difference: Agilent Technologies Inc pays a 0.78% dividend while Global X Uranium ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| A | URA | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $157.20 | $61.81 |
52-Week Low | $110.24 | $36.45 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
URA trades at $43.88, up 1.5% today, with a bearish technical signal driven by moving averages. The ETF's fundamentals are not detailed in standard ratios, but it focuses on uranium and nuclear energy companies. Recent news highlights strong thematic tailwinds from AI-driven power demand and government support for nuclear energy, positioning URA at the intersection of energy security and technology infrastructure growth.
Outlook is supported by structural demand from AI data centers and policy shifts, but risks include high expense ratios versus peers and concentrated exposure to uranium price volatility. Investor sentiment is cautiously optimistic given the nuclear renaissance narrative, though technical indicators suggest near-term consolidation near key support at $43.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →